Preclinical CRO
We are thought leaders in pharmacology and imaging.
With expertise in multiple therapeutic areas, our industry knowledgeable scientists provide seamless support for your R&D effort.
PDX models
Our process begins with the right model selection.
With our deep pharmacology and models expertise, your studies are implemented correctly from the beginning.
Molecular Imaging Preclinical Oncology
We stand beside you and your science.
With personalized attention, flexibility and responsiveness, we become an extension of your team.
Preclinical Imaging
We set the standard for industry relevant protocols.
We offer a broad array of efficient, validated pharmacology and imaging protocols to meet your needs.

Molecular Imaging, Inc. is a specialty CRO combining expertise in small animal in-vivo pharmacology and imaging. Our unique pharmaco-IMAGING platform allows for enhanced decision making in your discovery and development programs. 
For over 10 years, Molecular Imaging has provided pharmacology services and pioneered the application of multi-modality imaging. We have executed over 3,000 studies, 600 of which involved imaging, to more than 150 pharmaceutical and biotechnology clients. 

Latest Headlines

New studies highlight improvements in early tumor detection
21st Jan 2015
The early detection of breast cancer is integral to improving patients' prognoses, as doctors can begin treatment processes as soon as possible.
A new MRI technique may improve upon current diagnostic approaches toward prostate cancer.
21st Jan 2015
The type of prostate cancer treatment that doctors and patients agree upon depends in part on two factors that are observed via in vivo imaging: the size of the tumor, and its location.

Latest Video


18th Apr 2015
Philadelphia, PA

In the News


Have a look at the latest edition of Envision, Molecular Imaging, Inc.'s quarterly newsletter. Click Here




Preclinical Contract Research Organisation specializing in Multi-Modality Imaging studies across a wide range of Therapeutic Areas that enhance the effectiveness and efficiency of R&D decision making efforts for new drugs, biologics, devices and diagnostics.